Joe Pangenis
Analyst, H.D. Wainwright
Replay available
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q3 2025 earnings conference call, held 2025-11-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Raul Rodriguez
President and CEO
Dean Shorno
Chief Financial Officer
Lisa Royker
Chief Medical Officer
Ray Fury
Executive Vice President, General Counsel, and Corporate Secretary
Dave Santos
Chief Commercial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rigel Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.957 Greetings, and welcome to the Rigel Pharmaceuticals financial conference call for the 00:00:03.957 -- 00:00:06.782 third quarter 2025. At 00:00:06.782 -- 00:00:10.227 this time, all participants are in your listen-only mode. 00:00:10.227 -- 00:00:14.494 A brief question and answer session will follow the formal presentation. 00:00:14.494 -- 00:00:17.919 If anyone would require operator assistance during the conference, please press star 00:00:17.919 -- 00:00:20.583 zero on your telephone keypad. 00:00:20.583 -- 00:00:23.588 As a reminder, this conference is being recorded. 00:00:23.588 -- 00:00:28.766 It is my pleasure to introduce our first speaker, Ray Fury, Rigel's Executive Vice President, 00:00:28.766 -- 00:00:31.711 General Counsel, and Corporate Secretary. Thank you, Mr. 00:00:31.711 -- 00:00:32.452 Peer. You may begin. 00:00:32.452 -- 00:00:34.452 Welcome 00:00:35.417 -- 00:00:40.345 to our third quarter 2025 financial results and business update conference call. 00:00:40.345 -- 00:00:44.692 The financial press release for the third quarter 2025 was issued a short while ago and 00:00:44.692 -- 00:00:49.380 can be viewed along with the slides for this presentation in the news and events section 00:00:49.380 -- 00:00:53.103 of our investor relations site on Rigel.com. 00:00:53.103 -- 00:00:57.028 As a reminder, during today's call, we may make forward-looking statements regarding 00:00:57.028 -- 00:01:01.613 our financial outlook and our plans and timing for regulatory and product development. 00:01:01.613 -- 00:01:06.439 These statements are subject to risks and uncertainties that may cause actual results 00:01:06.439 -- 00:01:08.681 to differ from those forecasted. 00:01:08.681 -- 00:01:14.107 A description of these risks c...